Arap has been a Co-Leader of CIPT since 2020. He earned an MD from São Paulo Medical School in Brazil and a PhD in Cancer Biology from Stanford University. He completed internal medicine Residency at São Paulo Medical School University Hospitals, followed by a clinical fellowship in hematology/medical oncology at Memorial Sloan-Kettering Cancer Center. He joined Rutgers CINJ in 2018 as the Director of the Cancer Institute of New Jersey at University Hospital in Newark, leaving University of New Mexico Comprehensive Cancer Center where he was Deputy Director of the Cancer Center and Division Chief of Hematology/Oncology. Arap is an accomplished physician-scientist being a clinical expert in GU oncology and with a research focus on the development of novel cancer therapeutics targeting cancer specific molecules. Arap’s research program, run together with Renata Pasqualini, is based on the scientific premise that differential protein expression in disease tissues enables development of novel, targeted drugs to treat human disease. By integrating genomic analyses and analytical high-throughput analysis of protein-protein interactions, including innovative phage display methods, Arap has developed multiple novel approaches to targeted cancer therapy as well as vaccine development. He has a solid track record of funding from the NCI, including multiple R01 awards, served on the National Cancer Institute’s Board of Scientific Counselors, several review boards for the National Institutes of Health and the U.S. Department of Defense’s Prostate and Breast Cancer Research Programs in addition to several international funding agencies. He has multiple collaborations with investigators nationally and internationally and promising collaborations with CINJ investigators. As Director of the Rutgers CINJ at University Hospital, he is actively promoting basic, translational, and clinical research at the Newark campus.